Publikationen, an denen er mitarbeitet LUIS ANTONIO CORCHETE SÁNCHEZ (42)

2024

  1. Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers

    British Journal of Surgery, Vol. 111, Núm. 3

  2. Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling

    Haematologica, Vol. 109, Núm. 3, pp. 877-887

2023

  1. Clinical, Histopathologic and Genetic Features of Rhabdoid Meningiomas

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

  2. Predominantly Pro-Inflammatory Phenotype with Mixed M1/M2 Polarization of Peripheral Blood Classical Monocytes and Monocyte-Derived Macrophages among Patients with Excessive Ethanol Intake

    Antioxidants, Vol. 12, Núm. 9

  3. TMeB score may improve risk stratification of high-risk cutaneous squamous cell carcinoma and guide management of patients: A pilot study

    Journal of the European Academy of Dermatology and Venereology

  4. Telomere Length as a New Risk Marker of Early-Onset Colorectal Cancer

    International Journal of Molecular Sciences, Vol. 24, Núm. 4

2022

  1. Commentary: Genomic Analysis Reveals Heterogeneity Between Lesions in Synchronous Primary Right-Sided and Left-Sided Colon Cancer

    Frontiers in Molecular Biosciences

  2. Eltrombopag increases the hematopoietic supporting ability of mesenchymal stem/stromal cells

    Therapeutic Advances in Hematology, Vol. 13

  3. Expression of p53 protein isoforms predicts survival in patients with multiple myeloma

    American Journal of Hematology, Vol. 97, Núm. 6, pp. 700-710

  4. Recurrent NOMO1 Gene Deletion Is a Potential Clinical Marker in Early-Onset Colorectal Cancer and Is Involved in the Regulation of Cell Migration

    Cancers, Vol. 14, Núm. 16

  5. TCL-318 Evaluation of the Antitumor Activity of Amiloride in Peripheral T-Cell Lymphomas Using In-Vitro Models

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S399

  6. Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome

    British Journal of Haematology, Vol. 199, Núm. 3, pp. 344-354

2021

  1. A clinico-pathological and molecular analysis reveals differences between solitary (early and late-onset) and synchronous rectal cancer

    Scientific Reports, Vol. 11, Núm. 1

  2. Copy neutral loss of heterozygosity (cnLOH) patterns in synchronous colorectal cancer

    European Journal of Human Genetics, Vol. 29, Núm. 4, pp. 709-713

  3. Pathogenic convergence of CNVs in genes functionally associated to a severe neuromotor developmental delay syndrome

    Human Genomics, Vol. 15, Núm. 1

2020

  1. A New Next-Generation Sequencing Strategy for the Simultaneous Analysis of Mutations and Chromosomal Rearrangements at DNA Level in Acute Myeloid Leukemia Patients

    Journal of Molecular Diagnostics, Vol. 22, Núm. 1, pp. 60-71

  2. Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma

    Blood Advances, Vol. 4, Núm. 23, pp. 6023-6033

  3. Systematic comparison and assessment of RNA-seq procedures for gene expression quantitative analysis

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Comparing the eighth and the seventh editions of the American Joint Committee on Cancer staging system and the Brigham and Women's Hospital alternative staging system for cutaneous squamous cell carcinoma: Implications for clinical practice

    Journal of the American Academy of Dermatology, Vol. 80, Núm. 1, pp. 106-113.e2

2018

  1. Combined assessment of the TNM stage and BRAF mutational status at diagnosis in sporadic colorectal cancer patients

    Oncotarget, Vol. 9, Núm. 35, pp. 24081-24096